Eriocalyxin B is primarily studied for its potent anti-cancer properties. It has shown significant activity in inducing apoptosis in various cancer cell lines, including leukemia, liver, and breast cancer cells. The compound exerts its effects by targeting key signaling pathways such as NF-κB and MAPK, which play crucial roles in cell survival and proliferation. Due to its ability to trigger cell cycle arrest and promote mitochondrial dysfunction in tumor cells, it is considered a promising candidate for development in oncology therapeutics. Additionally, Eriocalyxin B exhibits anti-inflammatory effects, suggesting potential use in treating chronic inflammatory diseases. Research is ongoing to evaluate its efficacy and safety for future pharmaceutical applications.